3 ms·
Your link appears to not work, but for others' convenience I think this is what you meant to link: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD0
by pen2l 5y ago
Your link appears to not work, but for others' convenience I think this is what you meant to link: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub2/full https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD...
Separately, I'm having trouble parsing your comment, but I'm curious so I will ask: when you say "the boy rebuts", who is the boy here, yourself? Or..? Maybe I'm just not familiar with this turn of phrase.
- tptacek 5y agoSorry, my goofy kid is a graduating biochemistry senior and I keep him around the house for deployment in message board disputes.
- pen2l 5y agoWe begin to see why you are #1 in the leaderboard; you have help. But concerning controversy surrounding ivermectin I found this interesting text: An important controversial point to consider in any rationale is the 5 µM required concentration to reach the anti-SARS-CoV-2 action of ivermectin observed in vitro,17 which is much higher than 0.28 µM, the maximum reported plasma concentration achieved in vivo with a dose of approximately 1700 µg/kg (about nine times the FDA-approved dosification).24 25 In this sense, basic fundamentals for assessing ivermectin in COVID-19 at a clinical level appear to be insufficient. Among other reasons, we believe this might have led WHO to exclude ivermectin from its Solidarity Trial for repurposed drugs for COVID-19,12 which raises questions about the pertinence of conducting clinical studies on ivermectin. from BMJ, "Misleading clinical evidence and systematic reviews on ivermectin for COVID-19" -- https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111678 https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111...